Optimize The Formulation For A Monoclonal Antibody
Source: MilliporeSigma
An emerging biotech company sought help developing a formulation for a monoclonal antibody. The company didn’t have in-house development expertise and wanted a partner capable of delivering an optimized formulation of buffers and excipients within an aggressive timeline and budget. As with all formulations, it was essential that the buffers and excipients selected ensured the stability of the drug substance, were compatible with each other, and met regulatory requirements. Explore how MilliporeSigma delivered an optimized formulation for this customer in three months.
access the Case Study!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Biosimilar Development? Subscribe today.
Subscribe to Biosimilar Development
X
Subscribe to Biosimilar Development
MilliporeSigma
This website uses cookies to ensure you get the best experience on our website. Learn more